BRAF and lung carcinoma: 28, 34. In a study, which enrolled Asian populations, five non‐V600E mutations (four G469A and one G464E/G466R) exhibited concomitant EGFR mutations 22. Li et al. reported that five out of eight Chinese patients with lung adenocarcinoma and BRAF V600E mutation had concomitant EGFR mutations 35. Lung Cancer Mutation Consortium (LCMC) also reported that double‐mutation rate among patients with BRAF‐mutant NSCLC was 16% 25.